EmergingCognitiveLongevity

Dihexa(N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide)

Synaptogenic Peptide | Cognitive Enhancement

Half-life

8-12 days

Chain length

Not reported

Reference frequency

Once daily in the morning

Research overview

DoseGear research brief

Dihexa is a synthetic oligopeptide derived from angiotensin IV that potently enhances cognitive function by promoting synaptogenesis. It is 10 million times more potent than BDNF at promoting synapse formation through HGF/c-Met receptor activation.

Mechanism of action

Binds to hepatocyte growth factor (HGF) with high affinity (Kd = 65 pM) and potentiates its activity at c-Met receptor, activating PI3K/AKT pathways and promoting new synaptic connections with extraordinary potency.

Compound background

Development & research timeline

Study windows describe what researchers measured, not when an individual should expect a result.

Origin & development

Synthetic angiotensin-IV-derived compound.

What it is researched for

Preclinical cognition and synapse-formation research involving proposed HGF/c-Met-associated synaptogenic activity.

Research observation window

Not reported in the reviewed compound-specific evidence.

Reference data

Lyophilized vial injectable protocols

Not personalized dosing instructions

Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.

No sourced lyophilized-vial injectable protocol is listed for this profile.

Safety context

Reported side effects

Headaches (most frequent side effect)
Anxiety or overstimulation
Sleep disruption when dosed late in day
Mental clarity increase

Contraindications & cautions

Not FDA approved - research compound only
Theoretical cancer risk via c-Met activation
Cancer history (avoid due to c-Met pathway)
Pregnancy or breastfeeding
No long-term human safety data

Scientific references

01
Evaluation of Metabolically Stabilized Angiotensin IV Analogs as Procognitive/Antidementia Agents
Scientific citationEvaluation of Metabolically Stabilized Angiotensin IV Analogs as Procognitive/Antidementia Agents. Journal of Pharmacology and Experimental Therapeutics (2013).
02
AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway
Scientific citationAngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway. Brain Research Bulletin (2021).
03
The Procognitive and Synaptogenic Effects of Angiotensin IV-Derived Peptides Are Dependent on Activation of the Hepatocyte Growth Factor/c-Met System
Scientific citationThe Procognitive and Synaptogenic Effects of Angiotensin IV-Derived Peptides Are Dependent on Activation of the Hepatocyte Growth Factor/c-Met System. Journal of Pharmacology and Experimental Therapeutics (2014).
04
The Development of Small Molecule Angiotensin IV Analogs to Treat Alzheimer's and Parkinson's Diseases
Scientific citationThe Development of Small Molecule Angiotensin IV Analogs to Treat Alzheimer's and Parkinson's Diseases. Progress in Neurobiology (2015).

This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.

Related research profiles

Longevity